Double maintains 1 strategies that include FDMT - 4D Molecular Therapeutics, Inc.
Current Value
$3.201 Year Return
Current Value
$3.201 Year Return
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -33.30% | $361.41M | 1.43% |
VIXY | -29.43% | $109.64M | 0.85% |
TAIL | -24.98% | $140.49M | 0.59% |
IVOL | -13.80% | $353.94M | 1.02% |
TPMN | -11.19% | $31.54M | 0.65% |
KCCA | -10.36% | $97.18M | 0.87% |
AGZD | -8.99% | $127.42M | 0.23% |
STPZ | -8.88% | $446.46M | 0.2% |
CTA | -7.86% | $1.05B | 0.76% |
XONE | -6.92% | $603.24M | 0.03% |
CARY | -6.46% | $347.36M | 0.8% |
VTIP | -5.68% | $14.78B | 0.03% |
DBE | -5.52% | $48.48M | 0.77% |
FXE | -5.46% | $525.40M | 0.4% |
UDN | -5.25% | $137.74M | 0.78% |
KRBN | -5.17% | $160.09M | 0.85% |
SPTS | -5.14% | $5.76B | 0.03% |
USO | -5.05% | $956.18M | 0.6% |
TDTT | -4.68% | $2.47B | 0.18% |
STIP | -4.64% | $11.88B | 0.03% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
STOK | 45.02% | $525.77M | -31.36% | 0.00% |
IMNM | 44.64% | $696.10M | -44.44% | 0.00% |
KYMR | 43.62% | $1.95B | -15.67% | 0.00% |
RGNX | 43.18% | $433.39M | -46.03% | 0.00% |
IDYA | 43.02% | $1.52B | -58.32% | 0.00% |
BEAM | 42.95% | $1.73B | -27.49% | 0.00% |
DNLI | 42.44% | $2.06B | -30.04% | 0.00% |
RCKT | 42.27% | $724.54M | -71.26% | 0.00% |
APGE | 41.43% | $2.42B | -24.39% | 0.00% |
NTLA | 41.27% | $836.43M | -69.14% | 0.00% |
CMPS | 41.03% | $366.75M | -50.56% | 0.00% |
CRSP | 40.87% | $3.14B | -34.78% | 0.00% |
VTYX | 40.71% | $86.11M | -75.70% | 0.00% |
NNOX | 39.77% | $347.50M | -44.56% | 0.00% |
NRIX | 39.28% | $721.19M | -38.57% | 0.00% |
KRO | 38.79% | $799.50M | -47.43% | 4.89% |
YMAB | 38.78% | $174.80M | -67.43% | 0.00% |
EYPT | 38.74% | $393.60M | -54.31% | 0.00% |
COGT | 38.39% | $543.09M | -36.14% | 0.00% |
PLRX | 38.07% | $84.10M | -91.22% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
XBI | 49.64% | $4.85B | 0.35% |
GNOM | 49.42% | $40.65M | 0.5% |
ARKG | 46.09% | $944.78M | 0.75% |
IWC | 43.94% | $766.88M | 0.6% |
IBB | 43.93% | $5.22B | 0.45% |
PTH | 42.59% | $96.56M | 0.6% |
IWO | 41.15% | $11.36B | 0.24% |
CWB | 40.59% | $3.79B | 0.4% |
PBW | 39.65% | $269.08M | 0.65% |
ICVT | 39.48% | $2.46B | 0.2% |
VTWO | 39.09% | $12.07B | 0.07% |
IWM | 39.08% | $63.95B | 0.19% |
PBE | 39.01% | $214.12M | 0.58% |
KOMP | 38.73% | $2.20B | 0.2% |
KJUL | 38.68% | $113.35M | 0.79% |
CPRJ | 38.66% | $48.43M | 0.69% |
BBH | 38.63% | $327.42M | 0.35% |
NUSC | 38.37% | $1.14B | 0.31% |
SCHA | 38.34% | $16.91B | 0.04% |
VBK | 38.22% | $18.33B | 0.07% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
PLG | -0.02% | $115.89M | -32.32% | 0.00% |
OCX | 0.08% | $79.79M | -9.12% | 0.00% |
WM | 0.09% | $91.76B | +7.46% | 1.35% |
DUK | -0.14% | $90.12B | +12.74% | 3.61% |
KDP | -0.15% | $45.55B | -1.76% | 2.70% |
ZBH | -0.26% | $19.14B | -20.21% | 0.99% |
XEL | -0.32% | $41.10B | +27.59% | 3.10% |
AMT | 0.35% | $99.10B | +8.59% | 3.09% |
BDX | 0.41% | $49.37B | -27.20% | 2.32% |
DRD | 0.42% | $1.23B | +63.69% | 2.01% |
TEF | 0.45% | $27.20B | +8.80% | 6.44% |
PRT | -0.46% | $46.96M | +0.80% | 11.43% |
LFVN | 0.46% | $158.74M | +75.02% | 1.27% |
PINC | 0.53% | $1.88B | +15.22% | 3.69% |
MCK | 0.53% | $88.42B | +27.17% | 0.39% |
TR | 0.55% | $2.37B | +11.85% | 1.10% |
AU | 0.56% | $20.37B | +64.23% | 2.29% |
CORT | 0.58% | $7.78B | +166.38% | 0.00% |
BCE | 0.62% | $19.94B | -37.01% | 13.15% |
ZCMD | 0.66% | $32.45M | -11.38% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BILZ | -0.01% | $876.85M | 0.14% |
FTXG | 0.02% | $34.98M | 0.6% |
DBC | -0.04% | $1.17B | 0.87% |
JUCY | 0.09% | $297.77M | 0.6% |
ICSH | -0.12% | $6.10B | 0.08% |
IYK | 0.32% | $1.48B | 0.4% |
NEAR | -0.39% | $3.26B | 0.25% |
COMT | -0.48% | $606.15M | 0.48% |
CLIP | -0.49% | $1.50B | 0.07% |
FXC | -0.56% | $87.40M | 0.4% |
PDBC | -0.63% | $4.43B | 0.59% |
SHY | -0.65% | $24.03B | 0.15% |
SGOL | -0.65% | $5.06B | 0.17% |
SMB | -0.66% | $269.10M | 0.07% |
GLDM | -0.66% | $14.42B | 0.1% |
IBTH | -0.72% | $1.53B | 0.07% |
XBIL | -0.76% | $782.40M | 0.15% |
ASHR | 0.77% | $1.95B | 0.65% |
GLD | -0.82% | $96.70B | 0.4% |
KMLM | 0.82% | $188.32M | 0.9% |
Yahoo
EMERYVILLE, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on May 13, 2025, the compensation committee of the Company’s board of directors granted eight new non-executive employees 31,800 Restricted Stock Units (RSUs). The RSUs wer
Yahoo
4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of -2.38% and 98.70%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Yahoo
Enrolled first patients in first 4D-150 Phase 3 clinical trial (4FRONT-1) in wet AMD, with over 50 clinical trial sites open to dateInitiation of second 4D-150 Phase 3 clinical trial (4FRONT-2) expected in Q3 2025, with topline data from both 4FRONT-1 and 4FRONT-2 expected in H2 2027RMAT designation received from FDA for 4D-150 in DME, adding to previous regulatory designations of RMAT and PRIME (EMA) for 4D-150 in wet AMD$458 million in cash, cash equivalents, and marketable securities as of Ma
Yahoo
EMERYVILLE, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will participate in fireside chats at upcoming investor conferences in May. Members of the management team will also be available for one-on-one meetings. BofA S
Yahoo
The therapy leverages the company’s intravitreal vector, R100, invented using the Therapeutic Vector Evolution platform.
Yahoo
EMERYVILLE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that the U.S. Food and Drug Administration (FDA) has granted the Regenerative Medicine Advanced Therapy (RMAT) designation to 4D-150 for the treatment of diabetic macular edema
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CBOE | -17.10% | $22.95B | +20.67% | 1.12% |
K | -13.28% | $28.49B | +32.17% | 2.77% |
LITB | -12.49% | $21.28M | -72.45% | 0.00% |
VHC | -11.51% | $34.69M | +74.89% | 0.00% |
NOC | -10.86% | $67.51B | -0.35% | 1.76% |
GIS | -10.74% | $29.79B | -23.81% | 4.42% |
VZ | -9.90% | $183.32B | +8.02% | 6.21% |
CME | -9.37% | $98.74B | +28.80% | 3.84% |
KO | -8.60% | $308.23B | +13.09% | 2.75% |
MO | -8.31% | $97.80B | +26.35% | 6.94% |
ICFI | -8.18% | $1.63B | -39.65% | 0.64% |
HRL | -8.02% | $16.59B | -16.43% | 3.81% |
QXO | -7.85% | $8.44B | -84.99% | 0.00% |
CALM | -7.79% | $5.17B | +66.43% | 6.96% |
PGR | -7.66% | $164.82B | +35.81% | 1.74% |
GO | -7.61% | $1.37B | -35.98% | 0.00% |
CI | -7.51% | $82.51B | -8.96% | 1.84% |
CPB | -7.46% | $10.42B | -25.16% | 4.36% |
CAG | -7.12% | $10.87B | -26.52% | 6.17% |
CABO | -7.11% | $926.89M | -58.34% | 7.13% |